139 related articles for article (PubMed ID: 12682258)
1. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
[TBL] [Abstract][Full Text] [Related]
2. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT
J Immunol; 2007 Jul; 179(1):472-82. PubMed ID: 17579068
[TBL] [Abstract][Full Text] [Related]
3. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
[TBL] [Abstract][Full Text] [Related]
4. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.
Yip YL; Smith G; Koch J; Dübel S; Ward RL
J Immunol; 2001 Apr; 166(8):5271-8. PubMed ID: 11290813
[TBL] [Abstract][Full Text] [Related]
5. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
Garrett JT; Rawale S; Allen SD; Phillips G; Forni G; Morris JC; Kaumaya PT
J Immunol; 2007 Jun; 178(11):7120-31. PubMed ID: 17513761
[TBL] [Abstract][Full Text] [Related]
6. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
[TBL] [Abstract][Full Text] [Related]
7. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
Zhu L; Zhao L; Wu M; Chen Z; Li H
Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
[TBL] [Abstract][Full Text] [Related]
8. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
[TBL] [Abstract][Full Text] [Related]
9. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice.
Renard V; Sonderbye L; Ebbehøj K; Rasmussen PB; Gregorius K; Gottschalk T; Mouritsen S; Gautam A; Leach DR
J Immunol; 2003 Aug; 171(3):1588-95. PubMed ID: 12874253
[TBL] [Abstract][Full Text] [Related]
10. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
11. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
[TBL] [Abstract][Full Text] [Related]
12. Expression and purification of chimeric peptide comprising EGFR B-cell epitope and measles virus fusion protein T-cell epitope in Escherichia coli.
Wu M; Zhao L; Zhu L; Chen Z; Li H
Protein Expr Purif; 2013 Mar; 88(1):7-12. PubMed ID: 23220378
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.
Frangione-Beebe M; Albrecht B; Dakappagari N; Rose RT; Brooks CL; Schwendeman SP; Lairmore MD; Kaumaya PT
Vaccine; 2000 Dec; 19(9-10):1068-81. PubMed ID: 11137241
[TBL] [Abstract][Full Text] [Related]
14. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
[TBL] [Abstract][Full Text] [Related]
15. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.
Kaumaya PT
Hum Vaccin Immunother; 2015; 11(6):1368-86. PubMed ID: 25874884
[TBL] [Abstract][Full Text] [Related]
16. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
Singh R; Dominiecki ME; Jaffee EM; Paterson Y
J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
[TBL] [Abstract][Full Text] [Related]
17. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.
Seavey MM; Maciag PC; Al-Rawi N; Sewell D; Paterson Y
J Immunol; 2009 May; 182(9):5537-46. PubMed ID: 19380802
[TBL] [Abstract][Full Text] [Related]
18. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
[TBL] [Abstract][Full Text] [Related]
20. Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity.
Olszewska W; Obeid OE; Steward MW
Virology; 2000 Jun; 272(1):98-105. PubMed ID: 10873752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
